These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 25398067)

  • 21. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.
    Haberer JE; Baeten JM; Campbell J; Wangisi J; Katabira E; Ronald A; Tumwesigye E; Psaros C; Safren SA; Ware NC; Thomas KK; Donnell D; Krows M; Kidoguchi L; Celum C; Bangsberg DR
    PLoS Med; 2013; 10(9):e1001511. PubMed ID: 24058300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.
    Paltiel AD; Freedberg KA; Scott CA; Schackman BR; Losina E; Wang B; Seage GR; Sloan CE; Sax PE; Walensky RP
    Clin Infect Dis; 2009 Mar; 48(6):806-15. PubMed ID: 19193111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-serodiscordant couples desiring a child: 'treatment as prevention,' preexposure prophylaxis, or medically assisted procreation?
    Mabileau G; Schwarzinger M; Flores J; Patrat C; Luton D; Epelboin S; Mandelbrot L; Matheron S; Yazdanpanah Y
    Am J Obstet Gynecol; 2015 Sep; 213(3):341.e1-12. PubMed ID: 25979615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preexposure chemoprophylaxis for HIV prevention.
    Pimpinella G; Malgarini RB
    N Engl J Med; 2011 Apr; 364(14):1373; author reply 1374-5. PubMed ID: 21470024
    [No Abstract]   [Full Text] [Related]  

  • 27. [Pre-exposure prophylaxis for HIV transmission? No, unless].
    Boeke AJ; Heijnen AM
    Ned Tijdschr Geneeskd; 2013; 157(27):A6359. PubMed ID: 23838404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perceptions of emtricitabine-tenofovir in HIV PrEP.
    Kruse L; Stover K; Henderson H
    HIV Clin; 2014; 26(1):1, 4-7. PubMed ID: 24855688
    [No Abstract]   [Full Text] [Related]  

  • 29. When is good good enough for HIV-1 prophylaxis?
    Buchbinder S
    Lancet Infect Dis; 2014 Nov; 14(11):1024-1025. PubMed ID: 25300861
    [No Abstract]   [Full Text] [Related]  

  • 30. Sexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States.
    Liu AY; Vittinghoff E; Chillag K; Mayer K; Thompson M; Grohskopf L; Colfax G; Pathak S; Gvetadze R; Oʼhara B; Collins B; Ackers M; Paxton L; Buchbinder SP
    J Acquir Immune Defic Syndr; 2013 Sep; 64(1):87-94. PubMed ID: 23481668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV Prevention: Opportunities and Challenges.
    Marrazzo JM
    Top Antivir Med; 2017; 24(4):123-126. PubMed ID: 28208119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preexposure chemoprophylaxis for HIV prevention.
    Lee DH; Vielemeyer O
    N Engl J Med; 2011 Apr; 364(14):1372-3; author reply 1374-5. PubMed ID: 21470026
    [No Abstract]   [Full Text] [Related]  

  • 33. Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco.
    Liu A; Cohen S; Follansbee S; Cohan D; Weber S; Sachdev D; Buchbinder S
    PLoS Med; 2014 Mar; 11(3):e1001613. PubMed ID: 24595035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France.
    Lorente N; Fugon L; Carrieri MP; Andreo C; Le Gall JM; Cook E; Aboulker JP; Capitant C; Molina JM; Spire B
    AIDS Care; 2012; 24(4):468-77. PubMed ID: 22085083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco.
    Gilmore HJ; Liu A; Koester KA; Amico KR; McMahan V; Goicochea P; Vargas L; Lubensky D; Buchbinder S; Grant R
    AIDS Patient Care STDS; 2013 Oct; 27(10):560-6. PubMed ID: 24093809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Latent Class Analysis of Risk Factors for Acquiring HIV Among Men Who Have Sex with Men: Implications for Implementing Pre-Exposure Prophylaxis Programs.
    Chan PA; Rose J; Maher J; Benben S; Pfeiffer K; Almonte A; Poceta J; Oldenburg CE; Parker S; Marshall BD; Lally M; Mayer K; Mena L; Patel R; Nunn AS
    AIDS Patient Care STDS; 2015 Nov; 29(11):597-605. PubMed ID: 26389735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preexposure chemoprophylaxis for HIV prevention.
    Sellier PO; Lafuente-Lafuente C; Roques P
    N Engl J Med; 2011 Apr; 364(14):1373; author reply 1374-5. PubMed ID: 21470025
    [No Abstract]   [Full Text] [Related]  

  • 38. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Jan; 60(3):65-8. PubMed ID: 21270743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants.
    Fuchs JD; Sobieszczyk ME; Madenwald T; Grove D; Karuna ST; Andrasik M; Sherwat A; Broder G; Mayer K; Koblin B; Hammer S;
    J Acquir Immune Defic Syndr; 2013 Jul; 63(3):259-62. PubMed ID: 23614998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center.
    Mayer KH; Mimiaga MJ; Cohen D; Grasso C; Bill R; Van Derwarker R; Fisher A
    J Acquir Immune Defic Syndr; 2008 Apr; 47(4):494-9. PubMed ID: 18176318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.